Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation

Viracta Therapeutics Inc VIRX announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma.

• The data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting.
• Nana-val was well tolerated and demonstrated activity with complete responses observed across multiple EBV+ lymphoma subtypes and a median duration of response of 10.4 months.
• As of the October 28 data cutoff, 55 patients were enrolled. 
• Nana-val was generally well tolerated with reversible low-grade toxicities. 
• The most commonly observed treatment-emergent adverse events were reversible cytopenias, low-grade creatinine elevations, and gastrointestinal symptoms.
• Among evaluable patients (n=43), an overall response rate of 40% was observed across all lymphoma subtypes.
• Clinical Benefit Rate (CBR) was 56%.
• The median duration of response was 10.4 months, with three patients achieving responses with durations over two years.
• Last month, Viracta secured a $50 million credit facility from Silicon Valley Bank and Oxford Finance.
• Price Action: VIRX shares are are down 5.71% at $3.96 during the market session on the last check Monday.
• Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.